S7 Ep6: All Things Biosimilars: How Streamlined CES Rules Could Shift the Market

S7 Ep6: All Things Biosimilars: How Streamlined CES Rules Could Shift the Market

To learn more about the FDA draft guidance regarding clinical efficacy studies for biosimilars and interchangeability, click here [https://www.centerforbiosimilars.com/view/a-closer-look-at-new-fda-guidance-removing-barriers-to-biosimilar-development]. To read more about G's discussion with Sarah Yim, MD, from the FDA from the recent 2025 GRx+Biosims conference, click here [https://accessiblemeds.org/resources/blog/grxbiosims-2025-day-2-recap/]. To read more on Yim's perspectives on biosimilar policy harmonization, click here [https://www.centerforbiosimilars.com/view/calling-for-unified-biosimilar-standards-stronger-education-at-grx-biosims].

S7 Ep5: Follow the Science: Bridging the Biosimilar Gap

This special vodcast series provided by The Center for Biosimilars® was developed in partnership with the AAM and Biosimilars Council. Check out part 1 [https://www.centerforbiosimilars.com/view/escaping-the-void-all-things-biosimilars-with-craig-g] of the series featuring a discussion between Giuseppe Randazzo and Craig Burton, former executive director of the Biosimilars Council and current senior vice president of government affairs and policy at Fresenius Kabi. References Jeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars [https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars]

S7 Ep4: Escaping the Void: All Things Biosimilars With Craig & G

REFERENCE Jeremias S. The Biosimilar Void: 90% of Biologics Coming Off Patent Will Lack Biosimilars. February 5, 2025. Accessed May 3, 2025. https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars [https://www.centerforbiosimilars.com/view/the-biosimilar-void-90-of-biologics-coming-off-patent-will-lack-biosimilars]

S7 Ep3: How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment

Show notes  To learn more about the 10th anniversary of the first FDA biosimilar approval, click here [https://www.centerforbiosimilars.com/view/from-amjevita-to-zarxio-a-decade-of-us-biosimilar-approvals].  To learn more about how much biosimilars have saved so far, click here [https://www.centerforbiosimilars.com/view/aam-report-generics-and-biosimilars-savings-reach-445-billion-in-2023-part-1].  To read more about Josh's views on the pharmaceutical landscape in 2025, click here [https://www.pharmexec.com/view/the-shifting-pharmacy-landscape-in-2025].

S7 Ep2: Will the FTC Be More PBM-Friendly Under A Second Trump Administration?

Show notes  To learn more about the FTC's most recent report on PBMs, click here [https://www.centerforbiosimilars.com/view/ftc-releases-second-report-on-pbms-meddling-in-generic-drug-markets].  To learn more about the FTC's first report on PBMs, click here [https://www.ajmc.com/view/ftc-finds-pbms-drive-up-drug-costs-squeeze-out-competitors].  To learn more about health care actions taken by the second Trump Administration during it's first month, click here [https://www.ajmc.com/view/5-key-health-care-moments-during-president-trump-s-first-month-back-in-office].  To learn more about the views of Mehmet Oz, MD (more commonly known as Dr. Oz) on price transparency ahead of his congressional confirmation hearings as President Trump's nominee for HHS Secretary, click here [https://www.thestreet.com/investing/dr-oz-reveals-how-to-fix-healthcare-in-america-14346120].